Breaking News, Collaborations & Alliances

Lilly, Foghorn Enter Strategic Oncology Alliance

Development and commercialization agreement focused on Foghorn’s selective BRM oncology program leveraging its Gene Traffic Control platform.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Loxo Oncology at Lilly, a R&D group of Eli Lilly and Co., and Foghorn Therapeutics Inc. entered a strategic collaboration to create novel oncology medicines by applying Foghorn’s Gene Traffic Control platform. The collaboration includes a co-development and co-commercialization agreement for Foghorn’s selective BRM oncology program and an additional undisclosed oncology target. The collaboration also includes three additional discovery programs using Foghorn’s Gene Traffic ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters